Anixa Biosciences, Inc. ANIX
3.14 USD -0.04 (-1.26%)
Nov 9, 2026, 2:57 PM EST
3.09 Day range 3.30
2.32 52-week range 5.46
- YTD
- +0.48%
- 1 year
- -25.18%
News
prnewswire.com Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026 Dr. Robert Wenham, principal investigator of Anixa's Phase 1 clinical trial at Moffitt Cancer Center, to present on December 14 in London SAN JOSE, Calif., Nov. 4, 2026 /PRNewswire/ -- Anixa…
benzinga.com Anixa Biosciences Completes Dosing Of Fifth Group In Its Phase 1 Clinical Study Of FSHR-Targeted CAR-T Therapy To Treat Ovarian Cancer Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has completed dosing of the fifth
benzinga.com Anixa Biosciences Participant In Its Current Phase 1 Study Of FSHR-Targeted CAR-T Therapy For Recurrant Ovarian Cancer Demonstrates Stable Disease After 90 Days Of Treatment; Patient Was Treated In Fifth Dose Cohort Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that a patient in its ongoing Phase 1,
benzinga.com Anixa Biosciences Announces Second Patient Has Been Treated In Fifth Cohort Of Its Ongoing Phase 1, Dose-Escalating, Clinical Trial Evaluating FSHR-Targeted CAR-T Therapy For Recurrent Ovarian Cancer The study is being conducted at Moffitt Cancer Center ("Moffitt"). The Phase 1 study is evaluating a novel CAR-T therapy targeting follicle stimulating hormone receptor (FSHR), which is expressed on…
benzinga.com HC Wainwright & Co. Maintains Buy on Anixa Biosciences, Lowers Price Target to $6 HC Wainwright & Co. analyst Yi Chen maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and lowers the price target from $7 to $6.- benzinga.com IP Australia Grants Patent To Anixa Biosciences’ Breast Cancer Vaccine Technology, Exclusively Licensed From Cleveland Clinic Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in Australia through 2040, expanding the Company's growing global IP estateContinues expansion of global…
benzinga.com Anixa Biosciences Q3 EPS $(0.08) Beats $(0.09) Estimate, Sales $0.00, Same YoY Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 14.29 percent decrease over losses of…
benzinga.com Anixa Biosciences To Present Data On Its Breast Cancer Vaccine At 2026 Cantor Fitzgerald Global Healthcare Conference Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that management will participate in the…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Anixa Biosciences (NASDAQ:ANIX) shares rose 10.0% to $3.65 during Friday's pre-market session. The market value of their outstanding shares is at $112.9 million. Barinthus Biotherapeutics…
benzinga.com Anixa Biosciences Issued Notice Of Acceptance From IP Australia For Its Breast Cancer Vaccine Technology Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that IP Australia has issued a Notice of
benzinga.com Anixa Biosciences Doses First Participant In Fifth Group Of Its Phase 1 Clinical Study Of CAR-T/CER-T Therapy For Recurrent Ovarian Cancer Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the first patient has been treated in
benzinga.com Anixa Biosciences Receives Patent From South Korea's Ministry Of Intellectual Property For Its Breast Cancer Vaccine Technology Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Korean Ministry of Intellectual
benzinga.com Anixa Biosciences Announces Its Breast Cancer Vaccine's Final Phase 1 Data Shows All Major Primary Endpoints Met, Protocol-Defined Immune Responses Generated In 74% Of Participants Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its two clinical-stage immunotherapy
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com Anixa Biosciences Q2 EPS $(0.07) Beats $(0.09) Estimate Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 22.22 percent increase over losses of…
- benzinga.com Anixa Biosciences Secures Canadian Patent Allowance For AMHR2-Targeting Ovarian Cancer Vaccine Technology Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the prevention or treatment of ovarian cancerSAN JOSE, Calif., June 1, 2026 /PRNewswire/ -- Anixa…
- benzinga.com Anixa Biosciences Announces Its Data From Phase 1 Clinical Study Of Liraltagene Autoleucel Demonstrates No Dose-Limiting Toxicities To Treat Recurrent Ovarian Cancer Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced updated positive survival observations…
- benzinga.com Anixa Biosciences Receives Patent From Mexican Institute Of Industrial Property For Its Breast Cancer Vaccine Technology Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Mexican Institute of Industrial…
- benzinga.com Anixa Biosciences Reports Survival Data For Lira-cel In Phase 1 Trial At ISCT 2026 Conference Lira-cel continues to exhibit positive survival data in ongoing Phase 1 clinical trialSAN JOSE, Calif., April 22, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company")…
- benzinga.com Anixa Biosciences Enters Into Development And Manufacturing Agreement With Cytovance Biologics To Produce cGMP Clinical Materials For Planned Phase 2 Clinical Trial Of Breast Cancer Vaccine Phase 1 study met primary endpoints, showed safety and tolerability at the maximum tolerated dose, and generated protocol-defined immune responses in 74% of participantsSAN JOSE, Calif., April 1,…
- benzinga.com Anixa Biosciences To Present Ovarian Cancer CAR-T Therapy Clinical Trial At 2026 SGO Annual Meeting Dr. Robert Wenham of Moffitt Cancer Center and principal investigator of the trial to present lira-cel trial statusSAN JOSE, Calif., March 30, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or…
- benzinga.com Anixa Biosciences Receives South Korean Patent Allowance For Breast Cancer Vaccine Technology Licensed From Cleveland Clinic Notice of Allowance marks first Korean patent covering Anixa's breast cancer vaccine platformExpands global intellectual property coverage in markets with increasing breast cancer incidence rates and…
- benzinga.com Anixa Biosciences Issues Update On Patient Outcomes Observed In Ongoing Phase 1 Ovarian Cancer CAR-T Clinical Trial, Following Regulatory Approval Of Protocol Amendment That Enables Substantial Dose Escalation Multiple patients substantially exceed expected survival at low dose levels; absence of dose-limiting toxicities supports escalation to doses up to 100x higherTrial expansion reflects growing…
benzinga.com EXCLUSIVE: Anixa Biosciences' Ovarian Cancer Drug Candidate Shows Longer Survival With No Major Safety Issues Anixa Biosciences shares new data from its ovarian cancer trial, showing patients lived longer than expected with no serious safety concerns, as regulators approved a major dose increase.- benzinga.com EXCLUSIVE: Anixa Biosciences Reports Patient Data In Ovarian Cancer CAR-T Trial After Regulatory Approval; Says 'Multiple patients substantially exceed expected survival at low dose levels' The ongoing Phase 1 trial is enrolling adult women with recurrent ovarian cancer, who have failed standard of care chemotherapy, and progressed after two or more prior therapies. To date, twelve…
- benzinga.com D. Boral Capital Maintains Buy on Anixa Biosciences, Maintains $10 Price Target D. Boral Capital analyst Jason Kolbert maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and maintains $10 price target.
- benzinga.com Anixa Biosciences Says USAN Council Approves liraltagene autoleucel For Non-Proprietary Name Of Company's FSHR-Targeted CAR-T Therapy For Recurrent Ovarian Cancer Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Adopted Names…
- benzinga.com Anixa Biosciences Announces U.S. Adopted Names Council Approves Its Non-Proprietary Name For Its CAR-T Therapy For Recurrent Ovarian Cancer Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Adopted Names…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com Annexon Announces That The European Medicines Agency Has Selected Vonaprument To Participate In The Product Development Coordinator Pilot New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, Respond to Ad-hoc Queries, and Support Evidence PlanningVonaprument Selected by EMA as One of ~20…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 647 companies set new 52-week lows.
- benzinga.com Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's session, 454 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday Before 10 am on Friday, 110 companies set new 52-week lows.
- benzinga.com 77 Biggest Movers From Yesterday Gainers AMC Entertainment Holdings, Inc. (NYSE: AMC) shares surged 23.7% to close at $12.77. Moxian, Inc. (NASDAQ: MOXC) jumped 23.6% to close at $9.52.
- benzinga.com Mid-Day Market Update: Crude Oil Down 4.5%; Hoth Therapeutics Shares Spike Higher Midway through trading Tuesday, the Dow traded down 0.12% to 32,691.73 while the NASDAQ fell 0.23% to 13,346.14. The S&P also rose, gaining 0.01% to 3,940.97.
- benzinga.com Stocks That Hit 52-Week Highs On Thursday Before 10 a.m. ET on Thursday, 239 stocks hit new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Friday Before 10 a.m. ET on Friday, 571 companies hit new 52-week highs.
- benzinga.com 84 Biggest Movers From Yesterday Gainers
- benzinga.com 60 Stocks Moving In Thursday's Mid-Day Session Gainers Immutep Limited (NASDAQ: IMMP) shares jumped 198.6% to $6.42 after the company said its Chinese partner,
- benzinga.com Stocks That Hit 52-Week Highs On Thursday This morning 90 companies reached new 52-week highs.
- benzinga.com 58 Biggest Movers From Friday Gainers Xtant Medical Holdings, Inc. (NYSE: XTNT) shares climbed 91.4% to close at $1.57 on Friday after the company announced the closing of debt restructuring.
- benzinga.com 95 Biggest Movers From Yesterday Gainers Extraction Oil & Gas, Inc. (NASDAQ: XOG) shares climbed 247.9% to close at $1.48 on Monday following a 53% gain on Friday. The OPEC+ agreed to extend production cuts into July.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday
- benzinga.com 55 Biggest Movers From Yesterday
- benzinga.com Stocks That Hit 52-Week Lows On Friday
- benzinga.com 52 Biggest Movers From Yesterday